ProfileGDS5678 / 1428012_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 22% 22% 22% 22% 21% 22% 21% 21% 21% 22% 22% 22% 22% 22% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5418222
GSM967853U87-EV human glioblastoma xenograft - Control 22.514122
GSM967854U87-EV human glioblastoma xenograft - Control 32.5156922
GSM967855U87-EV human glioblastoma xenograft - Control 42.4585622
GSM967856U87-EV human glioblastoma xenograft - Control 52.4558121
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.5719422
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.5322221
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4898321
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4770121
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5012222
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.501722
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4830622
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.5069922
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.505122